- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
BriaCell Therapeutics Corp. is developing novel immunotherapies for metastatic breast cancer and is undergoing FDA review.
2 reports, 1 independent
Updated May 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BriaCell Therapeutics Corp. is developing novel immunotherapies for metastatic breast cancer and is undergoing FDA review.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- Unknown outlet